Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BJDX NASDAQ:BTCY NASDAQ:PAVM NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$1.75-1.7%$1.91$1.65▼$16.68$1.84M0.7222,769 shs4,825 shsBTCYBiotricity$0.20-18.5%$0.24$0.19▼$0.75$5.71M1.346,407 shs207,109 shsPAVMPAVmed$6.45+2.2%$9.22$6.00▼$28.44$6.28M0.6415,547 shs13,187 shsXAIRBeyond Air$0.47-12.6%$0.66$0.42▼$5.84$7.09M0.3375,459 shs292,567 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics-1.69%-3.85%-5.91%-34.46%-74.42%BTCYBiotricity-18.52%-23.19%-15.74%-24.10%-59.24%PAVMPAVmed+2.22%-9.66%-29.59%-38.28%-70.55%XAIRBeyond Air-12.61%-5.47%-17.54%-55.24%-87.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$1.75-1.7%$1.91$1.65▼$16.68$1.84M0.7222,769 shs4,825 shsBTCYBiotricity$0.20-18.5%$0.24$0.19▼$0.75$5.71M1.346,407 shs207,109 shsPAVMPAVmed$6.45+2.2%$9.22$6.00▼$28.44$6.28M0.6415,547 shs13,187 shsXAIRBeyond Air$0.47-12.6%$0.66$0.42▼$5.84$7.09M0.3375,459 shs292,567 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics-1.69%-3.85%-5.91%-34.46%-74.42%BTCYBiotricity-18.52%-23.19%-15.74%-24.10%-59.24%PAVMPAVmed+2.22%-9.66%-29.59%-38.28%-70.55%XAIRBeyond Air-12.61%-5.47%-17.54%-55.24%-87.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics 1.00SellN/AN/ABTCYBiotricity 0.00N/AN/AN/APAVMPAVmed 2.00Hold$65.00907.75% UpsideXAIRBeyond Air 2.33Hold$10.002,027.66% UpsideCurrent Analyst Ratings BreakdownLatest BJDX, PAVM, BTCY, and XAIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026XAIRBeyond Air Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PAVMPAVmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/9/2026PAVMPAVmed Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$510.00 ➝ $65.003/27/2026BJDXBluejay Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/18/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/10/2026XAIRBeyond Air D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay DiagnosticsN/AN/AN/AN/A$4.04 per shareN/ABTCYBiotricity$12.06M0.47N/AN/A($1.30) per share-0.15PAVMPAVmed$70K92.14N/AN/A($2.42) per share-2.67XAIRBeyond Air$3.70M1.68N/AN/A$3.32 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$6.85M-$11.63N/AN/AN/AN/A-144.27%-115.00%N/ABTCYBiotricity-$14.09M-$0.16N/AN/AN/A-80.42%N/A-188.47%6/26/2026 (Estimated)PAVMPAVmed$400K-$22.77N/AN/AN/A564.79%-242.99%-17.25%5/15/2026 (Estimated)XAIRBeyond Air-$46.62M-$5.43N/AN/AN/A-447.75%-268.82%-98.49%6/29/2026 (Estimated)Latest BJDX, PAVM, BTCY, and XAIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PAVMPAVmed-$0.69$999.00+$999.69$999.00$0.07 million$22.00 million5/7/2026Q1 2026BJDXBluejay DiagnosticsN/A-$1.95N/A-$1.95N/AN/A3/6/2026Q4 2025BJDXBluejay DiagnosticsN/A$3.23N/A$3.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A2.814.88BTCYBiotricityN/A0.230.10PAVMPAVmedN/A0.170.17XAIRBeyond Air2.655.124.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%BTCYBiotricity3.89%PAVMPAVmed19.93%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics0.08%BTCYBiotricity10.10%PAVMPAVmed13.40%XAIRBeyond Air9.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics91.03 million1.03 millionNot OptionableBTCYBiotricity4028.60 million22.08 millionNo DataPAVMPAVmed901.00 million863,000OptionableXAIRBeyond Air7013.19 million11.88 millionOptionableBJDX, PAVM, BTCY, and XAIR HeadlinesRecent News About These CompaniesBeyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026April 20, 2026 | globenewswire.comLucid, Beyond Air, Conagra stocks hit 52-week lows: What's behind the drag?April 16, 2026 | msn.comBeyond Air Appeals Nasdaq Notice on Listing ComplianceApril 15, 2026 | tipranks.comBeyond Air to Participate in the D. Boral Capital Global Conference 2026April 15, 2026 | globenewswire.comBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)April 1, 2026 | markets.businessinsider.comBeyond Air Names Robert Goodman as New CEOApril 1, 2026 | tipranks.comBeyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEOMarch 26, 2026 | markets.businessinsider.comBeyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO TrialMarch 17, 2026 | globenewswire.comBeyond Air to Participate in the 38th Annual Roth Conference in MarchMarch 11, 2026 | markets.businessinsider.comBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.March 10, 2026 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Beyond Air (XAIR)March 8, 2026 | theglobeandmail.comBeyond Air Inc (XAIR) Expands Focus on Nitric Oxide TherapiesMarch 4, 2026 | finance.yahoo.comHow The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed ApprovalFebruary 26, 2026 | finance.yahoo.comBeyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ...February 21, 2026 | finance.yahoo.comBeyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating ...February 20, 2026 | finance.yahoo.comBeyond Air, Inc. Highlights Comprehensive Review on High-Dose Inhaled Nitric Oxide as Potential Antimicrobial Therapy for Respiratory InfectionsFebruary 20, 2026 | quiverquant.comQBeyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory InfectionsFebruary 20, 2026 | globenewswire.comBeyond Air, Inc. Q3 2026 Earnings Call SummaryFebruary 14, 2026 | finance.yahoo.comBeyond Air, Inc. (NASDAQ:XAIR) Q3 2026 earnings call transcriptFebruary 14, 2026 | msn.comBeyond Air XAIR Q3 2026 Earnings Call TranscriptFebruary 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBJDX, PAVM, BTCY, and XAIR Company DescriptionsBluejay Diagnostics NASDAQ:BJDX$1.75 -0.03 (-1.69%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$1.76 +0.01 (+0.57%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Biotricity NASDAQ:BTCY$0.20 -0.05 (-18.52%) As of 05/14/2026 03:56 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.PAVmed NASDAQ:PAVM$6.45 +0.14 (+2.22%) Closing price 05/14/2026 03:49 PM EasternExtended Trading$6.68 +0.23 (+3.57%) As of 05/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Beyond Air NASDAQ:XAIR$0.47 -0.07 (-12.61%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.49 +0.02 (+4.26%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
